Granulomatosis with Polyangiitis (GPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Granulomatosis with Polyangiitis (GPA) is a systemic ANCA-associated granulomatous vasculitis whose lesions mainly affect the respiratory tract and kidneys. It can occur at any age, with a peak at 65-74 years of age. The disease can present with non-specific constitutional symptoms: malaise, myalgia, arthralgia, anorexia, and weight loss. It affects different organs, airways and renal involvement being the most frequent. The involvement of the upper airway is the most common and characteristic (70-100% at the time of diagnosis), mainly at the nasal and sinus levels, and may manifest with nasal discharge, epistaxis, nasal ulcers, perforation of the nasal septum, granulomatous lesions or destruction of facial cartilage with deformation of the nasal bridge, sinus or parasinus inflammation.
·
The annual incidence of Granulomatosis with
Polyangiitis (GPA) ranges between 5 to 10 cases per million population, and the
prevalence cases range between 56 to 89 cases per million.
Thelansis’s “Granulomatosis with
Polyangiitis (GPA) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Granulomatosis
with Polyangiitis (GPA) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Granulomatosis with Polyangiitis (GPA) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Granulomatosis with Polyangiitis (GPA)
Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment